

# WILSON SONSINI

## Derrick D. Rowe

PARTNER

Patents and  
Innovations  
Washington, D.C.

drowe@wsgr.com  
202-973-8894



## FOCUS AREAS

Biotech  
Intellectual Property  
Life Sciences  
Medical Devices  
Patents and Innovations

## EXPERIENCE

Dr. Derrick Rowe is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on patent prosecution and counseling designed to help clients protect their intellectual property rights both domestically and internationally in the life sciences, biotechnology, molecular biology, pharmaceutical, diagnostic, medical device, and digital health fields.

Derrick has extensive experience and has developed his practice in view of his experience in private practice as well as an in-house counsel at a large pharmaceutical company where he provided patent, contract, regulatory, and strategic counseling for pharmaceuticals and vaccines (including for multiple marketed products and related strategic partnerships).

Derrick is the author or co-author of eight peer-reviewed scientific articles and several published legal articles. He has also served as speaker/panelist/moderator in multiple life science settings and has guest lectured at various universities generally and specifically at schools of law, medicine, and business on the topics of intellectual property, licensing, and entrepreneurship.

## CREDENTIALS

### Education

- J.D., The George Washington University Law School
- Ph.D., Medical Sciences, University of South Florida
- M.S., Medical Sciences, University of South Florida
- B.S., Chemistry, University of Florida

### Honors

- Recognized among *The National Law Journal's* 2025 "D.C. Rising Stars"
- Named a "U.S. Rising Star" finalist in the Intellectual Property category for the *LMG Life Sciences* 2024 Americas Awards

### Admissions

- Bar of the District of Columbia
- State Bar of Virginia
- U.S. Patent and Trademark Office

## MATTERS

### Select Clients and Transactions

- Odyssey Therapeutics, Inc. on patent matters related to IPO
- RhizeBio, Inc. in connection with its acquisition by Holganix, Inc.
- Celmatix Inc. in connection with its acquisition by Gedeon Richter Plc
- Atsena Therapeutics in connection with its oversubscribed \$150 million Series C financing

- Opus Genetics, Inc. in connection with its acquisition by Ocuphire Pharma, Inc.
- Tenaya Therapeutics in connection with its \$50 million underwritten offering
- Metagenomi, Inc. in connection with its \$93 million IPO
- BigHat Biosciences in connection with its research collaboration with AbbVie having an upfront payment of \$30 million and up to approximately \$325 million in aggregate research and development milestones, with the potential for further commercial milestones, as well as tiered royalties on net sales
- Metagenomi, Inc. in connection with its oversubscribed Series B financing totaling \$275 million
- Tenaya Therapeutics in connection with its public offering
- Triumvira Immunologics, Inc. in connection with its \$55 million in Series A funding
- Karius Inc. in connection with its \$165 million in Series B funding
- Locus Biosciences in connection with its up-to-\$818 million deal with J&J
- DNALite in connection with its \$1.5 million in Seed funding
- Cambridge Epigenetix Limited in connection with its \$28.8 million Series B financing
- Medeor Therapeutics, Inc. in connection with its \$57 million Series B financing
- NantHealth in connection with its IP strategy and its \$91 million IPO

## INSIGHTS

---

### Select Publications

- Co-author, “Federal Circuit Provides Path to Written Description and Enablement for Patents Related to Methods of Using a Well-Known Class of Molecules,” Wilson Sonsini Alert, May 7, 2026
- Co-author, “USPTO Appeals Review Panel Addresses Obviousness-Type Double Patenting,” Wilson Sonsini Alert, March 12, 2026
- Co-author, “Failure to Provide Correct Inventors to the USPTO Results in Unenforceable Patents,” Wilson Sonsini Alert, December 10, 2025
- Co-author, “FDA Moves to Streamline Biosimilar Development: Implications for Regulatory Strategy and Clinical Study Design,” Wilson Sonsini Alert, November 13, 2025
- Co-author, “FDA’s Release of Complete Response Letters Raises Questions Related to Intellectual Property,” Wilson Sonsini Alert, September 26, 2025
- Co-author, “Federal Circuit Issues First Precedent on AIA Derivation Proceedings Regarding *Global Health Solutions v. Selner*,” Wilson Sonsini Alert, September 26, 2025
- Co-author, “Inventor’s Failure to Provide Material Information to the USPTO Results in an Unenforceable Patent,” Wilson Sonsini Alert, September 04, 2025
- Co-author, “Department of Commerce Initiates Bayh-Dole Compliance Review and Asserts March-In Proceeding Targeting Harvard University Patents,” Wilson Sonsini Alert, August 14, 2025
- Co-author, “Method of Treatment Claim’s Limiting Preamble Must Satisfy the Written Description Requirement,” Wilson Sonsini Alert, May 01, 2025
- Co-author, “Proposed Rulemaking Issued by the DOJ Covering Data Export Transactions with Entities from Countries of Concern,” Wilson Sonsini Alert, November 22, 2024
- Co-author, “The Inflation Reduction Act’s Medicare Price Negotiation Program: Two Years Later,” Wilson Sonsini Alert, November 20, 2024
- Co-author, “Federal Circuit Provides Guidance on What Claims Can Properly Serve As Obviousness-Type Double Patenting References,” Wilson Sonsini Alert, August 21, 2024
- Co-author, “USPTO Proposes New Requirement for Terminal Disclaimers That Amounts to a Significant Change from Current Practice,” Wilson Sonsini Alert, May 15, 2024
- Co-author, “Opportunity for Innovative Companies to Shape U.S. Patent and Trademark Office Initiatives,” Wilson Sonsini Alert, May 2, 2024
- Co-author, “Newly Amended Chinese Implementing Rules for Patent Law and Guidelines for Patent Examination Bring Significant Changes to Patenting Strategy in China,” Wilson Sonsini Alert, April 3, 2024
- Co-author, “New York Redefines the Permissible Scope of Invention Assignment Provisions,” Wilson Sonsini Alert, March 6, 2024
- Co-author, “Bipartisan Legislation Seeks to Clarify Which Inventions Are Patent Eligible,” *Intellectual Property & Law Journal*, February 9, 2024
- Co-author, Draft Guidance Puts March-In Authority Pursuant to Bayh-Dole in the News Once Again,” Wilson Sonsini Alert, December 22, 2023
- Co-author, “EPO’s ‘10-Day Rule’ to End October 31, 2023, ‘7-Day Rule’ to Begin November 1, 2023,” Wilson Sonsini Alert, September 18, 2023
- Co-author, “HHS Names the First 10 Drugs for Medicare Price Negotiation,” Wilson Sonsini Alert, September 5, 2023
- Co-author, “Major Change to European Patent System in 2023 to Impact Patent Owners’ Portfolios,” Wilson Sonsini Alert, October 21, 2022
- Co-author, “Prescription Drug Provisions in the Inflation Reduction Act of 2022,” JD Supra, August 30, 2022

- Co-author, "Basics of the Bayh-Dole Act: FAQs," Wilson Sonsini Client Advisories, July 6, 2020
- Co-author, "Cures Revolution May Reshape Pharmaceutical Landscape," *Law360*, June 14, 2018
- Co-author, "USPTO Implements Post-Prosecution Pilot Program," Wilson Sonsini Alert, July 15, 2016
- Co-author, "The Retrospective Approach To Companion Diagnostics," *Law360*, June 5, 2015
- Co-author, "The Rise Of Companion Diagnostics In Personalized Medicine," *Law360*, June 5, 2015

## Select Speaking Engagements

- Moderator, "Leveraging Patent Strategies for Successful Biotech-Pharma Collaborations," Wilson Sonsini Biotech Summit, Boston, Massachusetts, October 2025
- Speaker, "IP Strategy for Startups," CvilleBioHub, Charlottesville, Virginia, August 2025
- Speaker, "Protecting What You Build," iLab, Charlottesville, Virginia, July 2025
- Speaker, "Patents Strategy for Early stage life science company," Portal Innovations, Boston, Massachusetts, February 2025
- Guest lecturer, Frontiers in Biotech I, University of Virginia, Charlottesville, Virginia, February 2025
- Guest Lecturer, Intellectual Property Licensing Law, Temple University Beasley School of Law, Philadelphia, Pennsylvania, 2024
- Guest Lecturer, Frontiers in Biotech II, University of Virginia, Charlottesville, Virginia, 2024
- Speaker, "Life Science Bootcamp with Wilson Sonsini: Insights on Business, IP, Corporate and Regulatory Challenges," North Carolina Biotechnology Center, October 2023
- Speaker, "Entrepreneur Bootcamp," Lab Central, October 2023
- Moderator, "Emerging Innovations: North Carolina's Startup Showcase," LaunchBio, Durham, North Carolina, May 2023
- Speaker, "Entrepreneur Bootcamp," The George Washington University, February 2023
- Panelist, "FDA-PTO Roundtable," GW Law, January 21, 2022
- Guest lecturer, Intellectual Property Licensing Law, Temple University Beasley School of Law, 2021
- Moderator, "The Work Behind a Coronavirus Vaccine," Webinar, LaunchBio, April 16, 2020
- Moderator, "Non-Dilutive Funding for life Science Startups," LaunchBio, Durham, North Carolina, March 5, 2020
- Speaker, "Blockchain in Healthcare—Boom, Bogus, or Bust!" Society of Physician Entrepreneurs, Inova Personalized Health Accelerator, Fairfax, Virginia, May 9, 2018
- Speaker, "Recent Trends in Venture Markets and Financing," Technology Commercialization Office 2018 Start-Up Showcase, The George Washington University, Washington, D.C., April 17, 2018

## TECHNICAL FLUENCY

---

### Biological Sciences and Biotechnology

- Antibody
- Antigen presentation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell therapy
- Cellular biology
- Cellular immunology
- Epigenetics
- Genetics
- Genomics
- Host-pathogen interactions
- Immuno-oncology
- Immunobiology
- Immunology
- Microbiology
- Molecular biology
- Molecular genetics
- Neurobiology
- Phage therapy
- Stem cell biology
- T and B cell biology

- T cell biology
- T cell immunology

## **Therapeutics and Drug Discovery**

- Antimicrobial agents
- Biosimilars
- CRISPR
- Drug conjugates
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets
- Neuropharmacology
- Peptide therapeutics
- RNA interference (RNAi)
- Small molecules
- Vaccines

## **Diagnostics and Medical Devices**

- Biomedical devices
- Diagnostics

## **Chemistry and Material Science**

- Chemistry
- Polymorph
- Protein engineering
- Protein folding

## **Engineering and Technology**

- AI

## **Genomics and Data Analysis**

- Functional genomics
- Sequencing
- shRNA

## **Miscellaneous**

- Cancer
- Design patent
- Engineered foods
- Food science
- Formulations
- Infectious diseases
- Physiology
- Plant patents